Livforsakringsbolaget Skandia, Omsesidigt Neurocrine Biosciences Inc Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.73 Billion
- Q1 2025
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 1,000 shares of NBIX stock, worth $122,820. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$122,820
Previous $136,000
19.12%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding NBIX
# of Institutions
652Shares Held
97.3MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.74 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.22 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$680 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$597 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$328 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...